A series of benzo[g]benzothiazolo[2,3-b]quinazoline-7,12-quinones were prepared from 2-acylnaphthohydroquinones and 2-aminobenzothiazoles and were evaluated for their in vitro antiproliferative activity. After screening using the MTT reduction assay, their IC50 values were calculated on a panel of cancer cells (T24, DU-145, MCF-7). Current standard anticancer drugs were included as control, and their calculated IC50 values were 7.8 and 23.5 µM for 5-fluorouracil and tamoxifen, respectively. Non-cancer cells (AG1523) were included to assess cancer cell sensitivity and drug selectivity. Four members of the series, with IC50 values from 0.11 to 2.98 µM, were chosen for further assays. The selected quinones were evaluated regarding their effects on cancer cell proliferation (clonogenic assay) and on Hsp90 and poly(ADPribose)polymerase (PARP) protein integrity. The most active compound (i.e., 15) substantially inhibited colony forming unit (CFU) formation at 0.25 µM. In the presence of ascorbate, it induced an oxidative cleavage of Hsp90 but had no effect on PARP protein integrity. In an in vivo animal model, it discreetly increased the mean survival time (m.s.t.) of tumor-bearing mice. In light of these results, compound 15 represents a potential lead-molecule to be further developed.
一系列苯并[g]苯并噻唑[2,3-b]喹唑啉-7,12-醌类化合物是通过2-酰基萘羟喹醌和2-氨基苯并噻唑反应制备的,并对它们的体外抗增殖活性进行了评估。通过MTT还原实验筛选后,在一系列癌细胞(T24、DU-145、MCF-7)中计算了它们的IC50值。当前标准的抗癌药物被包括为对照,5-氟尿嘧啶和他莫昔芬的计算IC50值分别为7.8和23.5微米。非癌细胞(AG1523)被包括以评估癌细胞的敏感性和药物选择性。系列中的四个成员,其IC50值从0.11到2.98微米不等,被选定进行进一步的实验。选定的醌类化合物被评估其对癌细胞增殖(克隆形成实验)以及对Hsp90和聚(ADP核糖)聚合酶(PARP)蛋白完整性的影响。最活性的化合物(即15号)在0.25微米下显著抑制了克隆形成单位(CFU)的形成。在抗坏血酸存在的情况下,它诱导了Hsp90的氧化裂解,但对PARP蛋白的完整性没有影响。在体内动物模型中,它轻微增加了携带肿瘤的小鼠的平均存活时间(m.s.t.)。鉴于这些结果,化合物15代表了一个有潜力进一步开发的先导分子。